title: [A case of unresectable pancreatic cancer that responded to UFT chemotherapy].
abstract: A 77-year-old patient with an unresectable pancreatic cancer was treated with a combination chemotherapy of UFT (600 mg/day, p.o.) and Lentinan (2 mg/week, i.v.). After three and a half months, a partial response (PR) was achieved, based on the criteria of Koyama, Saito, et al. The findings of the follow up CT scans suggested that 600 mg/day of UFT, rather than 300 mg/day, was effective as a chemotherapeutic agent. Although transient thrombocytopenia (62,000/mm2) and eruption were observed during this therapy, no serious side effects were experienced. After eighteen months of this chemotherapy, the patient has not succumbed and manifests a good quality of life.
authors.affiliation: Dept. of Int. Med., Japanese Red Cross Nagoya 1st Hospital.
authors.forename: Y
authors.initials: Y
authors.lastname: Sato
authors.forename: T
authors.initials: T
authors.lastname: Sakai
authors.forename: T
authors.initials: T
authors.lastname: Okada
authors.forename: Y
authors.initials: Y
authors.lastname: Sasano
authors.forename: T
authors.initials: T
authors.lastname: Ando
authors.forename: J
authors.initials: J
authors.lastname: Haruta
authors.forename: K
authors.initials: K
authors.lastname: Kanayama
authors.forename: Y
authors.initials: Y
authors.lastname: Kuwahara
authors.forename: H
authors.initials: H
authors.lastname: Tachino
authors.forename: H
authors.initials: H
authors.lastname: Tahara
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D007912:Lentinan / Q000008:administration & dosage; D008297:Male; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D012074:Remission Induction; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
chemical_list: D005641:Tegafur; D007912:Lentinan; D014498:Uracil